NorthStrive Biosciences Inc., a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), filed a U.S. patent application covering pharmaceutical formulations and dosing regimens for its EL-22 myostatin-engineered probiotic treatment.

The application, numbered U.S. Patent Application No. 19/655,160, covers treatment of muscle-wasting conditions including muscle loss associated with GLP-1 receptor agonist therapy, sarcopenia, muscle disuse atrophy, and certain neurological disorders.

EL-22 uses a myostatin engineered probiotic approach designed to support muscle preservation and growth. The technology targets patients undergoing weight loss treatments such as GLP-1 receptor agonists, older adults with sarcopenia, patients with muscle disuse atrophy following injury or hospitalization, and individuals with certain neurological disorders.

The patent application includes claims for pharmaceutical compositions, formulations, and dosing regimens for use in human patients across multiple muscle-wasting indications. The filing is part of NorthStrive's strategy to build an intellectual property portfolio around EL-22 covering composition, formulation, and method-of-use claims.

NorthStrive describes itself as a biopharmaceutical company focused on developing therapeutic technologies for muscle preservation, metabolic health, and related conditions. PMGC Holdings operates as a diversified holding company managing a portfolio through strategic acquisitions and investments across multiple industries.

The company noted this press release was updated to provide expanded description of the patent application scope, with no changes to the underlying patent filing, application number, or filing date.